Zeal Asset Management Ltd Sells 341,789 Shares of HUTCHMED (China) Limited (NASDAQ:HCM)
Zeal Asset Management Ltd Sells 341,789 Shares of HUTCHMED (China) Limited (NASDAQ:HCM)
Zeal Asset Management Ltd cut its position in HUTCHMED (China) Limited (NASDAQ:HCM – Get Rating) by 44.8% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 421,140 shares of the company's stock after selling 341,789 shares during the period. HUTCHMED accounts for about 10.5% of Zeal Asset Management Ltd's investment portfolio, making the stock its 3rd biggest position. Zeal Asset Management Ltd owned 0.24% of HUTCHMED worth $5,075,000 at the end of the most recent reporting period.
根据热情资产管理有限公司在最近向美国证券交易委员会披露的信息,该公司在第二季度将其在和黄医药(中国)有限公司(纳斯达克代码:HCM-GET评级)的持仓削减了44.8%。该机构投资者在此期间出售了341,789股后,持有该公司421,140股股票。和黄医药在热情资产管理有限公司的投资组合中约占10.5%,这使该股成为其第三大头寸。截至最近一次报告期末,热心资产管理有限公司持有和黄医药0.24%的股份,价值5,075,000美元。
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in HCM. Quantbot Technologies LP bought a new position in shares of HUTCHMED in the first quarter worth about $44,000. US Bancorp DE raised its stake in shares of HUTCHMED by 270.9% during the first quarter. US Bancorp DE now owns 3,687 shares of the company's stock worth $70,000 after buying an additional 2,693 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of HUTCHMED by 5.6% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,767 shares of the company's stock worth $317,000 after buying an additional 892 shares during the last quarter. Invesco Ltd. raised its stake in shares of HUTCHMED by 18.1% during the first quarter. Invesco Ltd. now owns 17,007 shares of the company's stock worth $322,000 after buying an additional 2,609 shares during the last quarter. Finally, Asset Management One Co. Ltd. raised its stake in shares of HUTCHMED by 10.9% during the second quarter. Asset Management One Co. Ltd. now owns 17,519 shares of the company's stock worth $221,000 after buying an additional 1,724 shares during the last quarter. 27.37% of the stock is currently owned by institutional investors and hedge funds.
其他一些机构投资者和对冲基金最近也增持或减持了HCM的股份。今年第一季度,Quantbot Technologies LP购买了和黄医药的新头寸,价值约44,000美元。第一季度,US Bancorp DE增持和黄医药股份270.9%。US Bancorp DE现在拥有3687股该公司股票,价值7万美元,此前在上个季度又购买了2693股。苏黎世广东银行在第一季度增持了5.6%的和黄医药股份。Zurcher Kantonalbank苏黎世广东银行在上个季度额外购买了892股后,现在拥有16,767股该公司股票,价值317,000美元。景顺股份有限公司在第一季度增持了18.1%的和黄医药股份。景顺公司目前持有17,007股该公司股票,价值322,000美元,上一季度又购买了2,609股。最后,资产管理一号在第二季度增持了10.9%的和黄医药股份。Asset Management One Co.Ltd.现在持有17,519股该公司股票,价值221,000美元,该公司在上个季度又购买了1,724股。27.37%的股票目前由机构投资者和对冲基金持有。
Analysts Set New Price Targets
分析师设定新的价格目标
HCM has been the subject of a number of recent research reports. The Goldman Sachs Group boosted their price target on shares of HUTCHMED from $14.00 to $16.00 and gave the stock a "neutral" rating in a research note on Tuesday, August 9th. StockNews.com initiated coverage on shares of HUTCHMED in a research note on Wednesday, October 12th. They issued a "hold" rating for the company.
HCM是最近一些研究报告的主题。8月9日,在周二的一份研究报告中,高盛夫妇将和黄医药的目标价从14.00美元上调至16.00美元,并给予该股“中性”评级。斯托克新闻网在10月12日星期三的一份研究报告中首次对和黄医药的股票进行了报道。他们对该公司的评级为“持有”。
HUTCHMED Stock Up 2.3 %
和黄医药股价上涨2.3%
About HUTCHMED
关于和黄医药
(Get Rating)
(获取评级)
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors.
和黄医药(中国)有限公司在香港和国际上发现、开发癌症和免疫疾病的靶向治疗和免疫疗法,并将其商业化。它在肿瘤学/免疫学和其他风险投资领域开展业务。该公司开发Savolitinib,一种治疗非小细胞肺癌(NSCLC)、乳头状细胞癌和肾癌、结直肠癌(CRC)和胃癌(GC)的抑制剂;以及Fruquintinib,一种治疗CRC、乳腺癌、GC、子宫内膜癌(EMC)、非小细胞肺癌、肝细胞癌以及胃肠道和实体肿瘤的抑制剂。
Read More
阅读更多内容
- Get a free copy of the StockNews.com research report on HUTCHMED (HCM)
- Should Investors Raise a Glass to Boston Beer Company?
- MarketBeat: Week in Review 10/17-10/21
- The Institutions Spin Whirlpool Into Bargain Basement Territory
- American Express Beats Earnings & Revenue Views, Raises Guidance
- Snap Stock Falls As User Growth Slows To Single-Digits
- 免费获取斯托克新闻网关于和黄医药的研究报告
- 投资者应该向波士顿啤酒公司举杯吗?
- MarketBeat:回顾一周10/17-10/21
- 机构将惠而浦打入廉价地下室领域
- 美国运通业绩超过盈利和收入预期,提高业绩指引
- Snap股价下跌,用户增长放缓至个位数
Receive News & Ratings for HUTCHMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHMED and related companies with MarketBeat.com's FREE daily email newsletter.
接受《和黄医药日报》的新闻和评级-在下面输入您的电子邮件地址,即可通过MarketBeat.com的免费每日电子邮件时事通讯接收对和黄医药及相关公司的最新新闻和分析师评级的每日摘要。